Utility of individualized homoeopathic medicine in managing pain of adhesive capsulitis : A prospective open label observational clinical study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Primary endpoint
Study Overview
Brief Summary
Adhesivecapsulitis, commonly referred to as frozen shoulder, is associated withsynovitis and capsular contracture of the shoulder joint and can be classifiedas either primary or secondary. In presentscenario homoeopathic medicines could be a valid alternative treatment to providea significant improvement in pain and stiffness along with significant benefiton overall well being of the patients. Unfortunately there isinsufficient evidence to make conclusion about the utility of individualisedhomoeopathic medicine in management of adhesivecapsulitis.
So a study is need to undertake toexplore the possible effects of individualized homoeopathic medicines inrelieving pain and stiffness, reduction in limitation, and disability inactivities of daily life in the patients suffering from adhesive capsulitis.
Theresearchers at CRU Siliguri proposed to undertake an open label observationalclinical study to evaluate the utility of individualized homoeopathy inmanagement of pain and stiffness in patients with adhesive capsulitis
Study Design
- Study Type
- Interventional
- Allocation
- Not Applicable
- Masking
- Not Applicable
Eligibility Criteria
- Ages
- 30.00 Year(s) to 70.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •1.Patients of both gender 2.Patients within age of 30-70 years 3.Patients presenting with clinical symptoms of adhesive capsulitis of one or both shoulder 4.Patients in the stage of acute/freezing/painful stage and adhesive/frozen stiffening phase of adhesive capsulitis 5.Patient willing to give informed consent.
Exclusion Criteria
- •1.Severe degeneration of shoulder joint with marked joint narrowing with recent shoulder surgery within last 6 months 2.Deformity of shoulder (>12o); evidence by imaging or other evidences and requiring surgical intervention 3.Self-reported joint disorders (e.g. inflammatory joint disease, specific arthropathy, severe axis deviations or instabilities, joint or skin infections, joint prosthesis of the upper limbs) other than adhesive capsulitis 4.Cases with other systemic diseases and with any vital organ failure and any self-reported immune-compromised states 5.Patients unwilling to give informed consent.
Outcomes
Primary Outcomes
Primary endpoint
Time Frame: Primary endpoint | Pain VAS score at the end of 2 months treatment.
Pain VAS score at the end of 2 months treatment.
Time Frame: Primary endpoint | Pain VAS score at the end of 2 months treatment.
Secondary Outcomes
- Secondary endpoint(•ORIDL and WHOQOL scale assessment after 2 months treatment.)